ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,599.30
      0.49%
      US Tech 100
      19,102.00
      1.26%
      Dow Jones
      41,350.93
      -0.20%
      Brent Oil
      70.69
      1.40%
      Bitcoin
      83,611.64
      0.92%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Verve Therapeutics Inc (VERV)

      7. Verve Therapeutics Inc (VERV) News

      Verve Therapeutics Inc

      Verve Therapeutics Inc (VERV)

      Verbund Ag
      Verbund Ag
      Verbund Ag
      Verbund Ag
      6.42
      0.26
      (4.22%)
      At close: March 12 4:00PM
      Delayed by 15 minutes
      6.42
      -0.01
      ( -0.16% )
      After Hours: 5:30PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      VERV News

      Official News Only

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      December 04 2024
      VERV (4.22%)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
      Edgar (US Regulatory)
      November 08 2024
      VERV (4.22%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      November 05 2024
      VERV (4.22%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 05 2024
      VERV (4.22%)

      VERV Discussion

      View Posts
      Monksdream Monksdream 2 weeks ago
      VERV 10Q due Monday 2/24
      👍️0
      Monksdream Monksdream 7 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 7 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 7 months ago
      VERV 10Q due AUGUST5
      👍️0
      Monksdream Monksdream 8 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 8 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 9 months ago
      VERV more new lows up ahead
      👍️0
      Monksdream Monksdream 10 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 10 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 11 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 11 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 11 months ago
      VERV new 52 lo
      👍️0
      Firestorm22 Firestorm22 11 months ago
      uh oh
      👍️0
      Monksdream Monksdream 11 months ago
      VERV over $10
      👍️0
      fink fink 1 year ago
      Looking for an entry now
      👍️0
      Terpi Terpi 1 year ago
      Could see another nice move here is the 50 day holds into close.
      👍️0
      Monksdream Monksdream 1 year ago
      VERV morning rally
      👍️0
      TheFinalCD TheFinalCD 2 years ago
      https://cathiesark.com/
      👍️0
      crudeoil24 crudeoil24 3 years ago
      VERV IS A GREAT $$$$$ OPPORTUNITY.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Verve Therapeutics started at outperform with $48 stock price target at BMO Capital
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s initial two programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
      👍️0

      Your Recent History

      NASDAQ
      VERV
      Verve Therapeutics
      BIT
      UC836T
      Unicredit Bank
      BIT
      F13700
      Vontobel Financial Produ...
      BIT
      EVAAXA
      Askoll EVA
      BIT
      F34740
      Vontobel Financial Produ...
      BIT
      UC3C88
      Unicredit Bank
      BIT
      UC8K2Y
      Unicredit Bank
      BIT
      GS0243
      Goldman Sachs Finance
      BIT
      UC4AZK
      Unicredit Bank
      BIT
      P1BO60
      BNP Paribas Issuance
      BIT
      CO2L1
      Sg Etc Carbon Future
      BIT
      EQLTD
      ETF
      BIT
      TRSY
      SSgA SPDR ETFs EUROPE I ...
      BOV
      EPRE6L
      Emp De Premoldados Sa Em... PNB
      BIT
      S24910
      SG ISSUER
      BIT
      UB591V
      Unicredit Bank
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads